Scientific Executive Director

Serving as Scientific Executive Director at Bristol Myers Squib, Shuichan Xu, PhD, leads drug discovery teams for novel cancer therapies using targeted protein degradation approaches. Shuichan has more than 20 years of drug discovery experience and has contributed to deliveries of multiple candidates for clinical development. Shuichan obtained her PhD in Molecular Biology and Virology from the Chinese Academy of Preventive Medicine in Beijing. She subsequently held postdoctoral positions in the laboratories of Melanie Cobb at UT Southwestern and Tony Hunter at the Salk Institute of Biological Studies, working on MAP kinase signal transduction and cell cycle regulation. From 2000, she entered the pharmaceutical industry, working as a scientist first at Structural Genomix and then Celgene working on high throughput screening of SCFSKP2/CKS1 E3 ligase. During her time at Celgene, Shuichan led drug discovery and translational research groups working on various projects including translational support of phase I clinical studies of mTOR kinase inhibitors CC-223 and CC-115, phenotypic screen leading to the discovery of CC-91516, a dual ERK/NLK kinase inhibitor, and AR LDD with the delivery of BMS-986365 for clinical development. Since 2016, Shuichan’s work has focused on targeting protein degradation through recruitment of cereblon.